News Feature

After an unusual year, M&A activity picked up again in the biopharma industry with a number of billion-dollar deals.

COVID-19 has accelerated development and awareness of next-generation therapeutics, including mRNA vaccines, boosting the field’s dealmaking and investment activities.

July was awash with financings of potentially disruptive gene therapies.

Recent deals involving bispecific antibodies illustrate the growing breadth of cancer immunotherapy applications for this platform.

Emma Dorey highlights five key deals, all from the US, in an otherwise quiet month.

This month we showcase the six-part Nature Careers podcast series, ‘Business of Science,’ which ran in May and June 2021 and aimed to teach new entrepreneurs about the first steps of research commercialization, from registering a patent, to scaling up and beyond.

Emma Dorey explores the latest series B financing rounds from a range of several small biotech companies.

Dealmaking in the central nervous system disorder field has been dynamic in the past year despite COVID-19, and the market for therapies is set to expand in the next 5 years.

The COVID-19 pandemic has put new vaccine technologies into the spotlight and accelerated their development.

Big pharma dealmaking returns to pre-pandemic levels as companies spend big to develop a range of cancer therapies.

Welcome to our May selection of key business of science stories from across Springer Nature’s portfolio of journals. This month we explore some stories based around COVID vaccines and bring to you the first two series of a Nature Careers ‘Business of Science’ podcast that aims to teach new entrepreneurs the first steps of research commercialization and patenting.

Emma Dorey highlights key IPOs, gene therapy and oncology announcements in the second of her monthly round-ups.

Plentiful financing and multiple pharma partnerships illustrate the burgeoning interest in applying artificial intelligence tools to drug research and development.

Approaches such as gene therapy and nucleic acid-based therapies are emerging in recent deals related to potential treatments for ophthalmic diseases.

Welcome to our latest round up of key business of science stories from across Springer Nature’s portfolio of journals. This month we look at how biotech funding flourished during the pandemic, and explore the latest information regarding both AstraZeneca’s and Johnson & Johnson’s vaccines in the rollout against COVID-19.

In the first of a new series exploring monthly financing biotech news, Emma Dorey examines a selection of noteworthy financings in the month of March.

Our monthly roundup of 'business of science' stories from across Springer Nature’s portfolio of journals explores the relationships between academia, startups and big pharma, as well as following the progress of the COVID-19 vaccine rollout.

A surge of efforts focused on the drug target B cell maturation antigen could transform the treatment of multiple myeloma and help to establish the relative merits and optimization strategies for emerging treatment modalities with wider applications.

After a slow start due to the COVID-19 pandemic, oncology dealmaking thrived in 2020 as immuno-oncology fueled a number of high-value drug licensing deals and a string of billion-dollar M&As were announced.

Our monthly round up of key biopharma business stories from across Springer Nature’s portfolio of journals, including the latest on COVID-19 vaccines and a focus on oncology.